2. Search Result
Search Result
Results for "

phosphoglycerate

" in MedChemExpress (MCE) Product Catalog:

26

Inhibitors & Agonists

2

Natural
Products

7

Recombinant Proteins

2

Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15154
    NG 52
    10+ Cited Publications

    Compound 52

    		 CDK Cancer
    NG 52 is a potent, cell-permeable, selective, ATP-compatible and orally active Cdc28p and Pho85p kinase inhibitor with IC50s of 7 μM and 2 μM, respectively. NG 52 also inhibits the activity of phosphoglycerate kinase 1 (PGK1) with an IC50 of 2.5 μM. NG 52 is inactive against yeast kinases Kin28p, Srb10, and Cak1p .
    NG 52
  • HY-100012
    CBR-5884
    Maximum Cited Publications
    20 Publications Verification

    		 Phosphoglycerate Dehydrogenase (PHGDH) Cancer
    CBR-5884 is an active, selective inhibitor of phosphoglycerate dehydrogenase (PHGDH) with an IC50 of 33 μM. CBR-5884 inhibits de novo serine synthesis in cancer cells and is selectively toxic to cancer cell lines with high serine biosynthetic activity. CBR-5884 selectively inhibits the proliferation of melanoma and breast cancer lines that have a high propensity for serine synthesis .
    CBR-5884
  • HY-141412
    D-(-)-3-Phosphoglyceric acid disodium
    1 Publications Verification

    3-Phospho-D-glyceric acid disodium

    		 Enolase Phosphoglycerate Dehydrogenase (PHGDH) MDM-2/p53 Apoptosis Infection
    D-(-)-3-Phosphoglyceric acid (3-Phospho-D-glyceric acid) disodium is an important intermediate in the enzyme-catalyzed glycolysis process. D-(-)-3-Phosphoglyceric acid disodium competitively inhibits yeast enolase (enolase). D-(-)-3-Phosphoglyceric acid disodium can regulate the activity of phosphoglycerate dehydrogenase (PHGDH) to modulate p53 protein and apoptosis .
    D-(-)-3-Phosphoglyceric acid disodium
  • HY-148510
    HKB99

    		Phosphatase Apoptosis Akt ERK Reactive Oxygen Species (ROS) Cancer
    HKB99 is an allosteric inhibitor of phosphoglycerate mutase 1 (PGAM1). HKB99 induces apoptosis. HKB99 inhibits the formation of invasive pseudopodia and inhibits migration. HKB99 increases the oxidative stress, activates JNK/c-Jun and suppresses AKT and ERK. HKB99 can be used for the research of non-small-cell lung cancer (NSCLC) .
    HKB99
  • HY-123269
    PKUMDL-WQ-2101

    		Phosphoglycerate Dehydrogenase (PHGDH) Cancer
    PKUMDL-WQ-2101 is a non-NAD +-competing allosteric phosphoglycerate dehydrogenase (PHGDH) inhibitor with an IC50 of 34.8 μM. PKUMDL-WQ-2101 exhibits antitumor activity .
    PKUMDL-WQ-2101
  • HY-126254
    BI-4924
    1 Publications Verification

    		 Phosphoglycerate Dehydrogenase (PHGDH) Cancer
    BI-4924 is a lipophilic, highly plasma protein bound selective phosphoglycerate dehydrogenase (PHGDH) inhibitor (IC50=3 nM) with excellent microsomal, as well as hepatocytic stability. Intracellular trapping of BI-4924 disrupts serine biosynthesis with an IC50 of 2200 nM at 72 h .
    BI-4924
  • HY-148570
    PHGDH-IN-3
    1 Publications Verification

    		 Phosphoglycerate Dehydrogenase (PHGDH) Cancer
    PHGDH-IN-3 is an orally active phosphoglycerate dehydrogenase (PHGDH) inhibitor. PHGDH-IN-3 inhibits PHGDH with an IC50 value of 2.8 μM. PHGDH-IN-3 can be used for the research of cancer .
    PHGDH-IN-3
  • HY-101143
    PGMI-004A

    		Phosphatase Cancer
    PGMI-004A is a potent phosphoglycerate mutase 1 (PGAM1) inhibitor with an IC50 of 13.1 μM.
    PGMI-004A
  • HY-117240
    NCT-502
    5+ Cited Publications

    		 Phosphoglycerate Dehydrogenase (PHGDH) Cancer
    NCT-502 is a human phosphoglycerate dehydrogenase (PHGDH) inhibitor, cytotoxic to PHGDH-dependent cancer cells, and reduces glucose-derived serine production, with an IC50 of 3.7 μM against PHGDH .
    NCT-502
  • HY-134205A
    CBR-470-1
    3 Publications Verification

    		 Keap1-Nrf2 Neurological Disease Metabolic Disease
    CBR-470-1 is an inhibitor of the glycolytic enzyme phosphoglycerate kinase 1 (PGK1). CBR-470-1 is also a non-covalent Nrf2 activator. CBR-470-1 protects SH-SY5Y neuronal cells against MPP +-induced cytotoxicity through activation of the Keap1-Nrf2 cascade .
    CBR-470-1
  • HY-128681
    PGAM1-IN-1
    1 Publications Verification

    		 Phosphatase Cancer
    PGAM1-IN-1 is a phosphoglycerate mutase 1 (PGAM1) inhibitor with an IC50 of 6.4 μM .
    PGAM1-IN-1
  • HY-P2822
    Phosphoglycerate kinase, yeast

    PGK

    		 Endogenous Metabolite Infection Endocrinology Cancer
    Phosphoglycerate kinase, yeast (PGK), namely phosphoglycerate kinase, is a glycolytic enzyme commonly used in biochemical research. Phosphoglycerate kinase can catalyze the reversible transfer of phosphate groups from 1,3-bisphosphoglycerate (1,3-BPG) to ADP to generate 3-phosphoglycerate (3-PG) and ATP. At the same time, it can also participate in gluconeogenesis, catalyzing the opposite reaction to produce 1,3BPGA and ADP. Phosphoglycerate kinase is involved in energy metabolism, interaction with nucleic acid, tumor progression, cell death and virus replication and other related processes .
    Phosphoglycerate kinase, yeast
  • HY-125273
    DNS-pE

    		Fluorescent Dye Phosphoglycerate Dehydrogenase (PHGDH) Others
    DNS-pE is a 3-phosphoglycerate dehydrogenase (PHGDH) inhibitor with a Ki of 7.4 μM. DNS-pE selectively and irreversibly covalently modifies endogenous PHGDH in live mammalian cells, its vinyl sulfone moiety acts as a fluorescence quencher that becomes highly fluorescent upon covalent modification of PHGDH. DNS-pE can be used as a fluorescent dye for live-cell imaging .
    DNS-pE
  • HY-128682
    PGAM1-IN-2

    		Phosphatase Cancer
    PGAM1-IN-2 is a phosphoglycerate mutase 1 (PGAM1) inhibitor with an IC50 of 2.1 μM .
    PGAM1-IN-2
  • HY-N8540
    Ilicicolin H

    		Phosphoglycerate Kinase (PGK) Fungal Apoptosis Infection Cancer
    Ilicicolin H is a selective and non-ATP-competitive phosphoglycerate kinase 1 (PGK1) (IC50 = 9.02 μM) and mitochondrial cytochrome bc1 reductase (IC50 = 2-3 ng/mL) inhibitor. Ilicicolin H directly binds to PGK1 with KD of 60 μM .Ilicicolin H can inhibit cell proliferation and induce apoptosis. Ilicicolin H can inhibit the lactate production and glucose uptake of hepatocellular carcinoma (HCC) cells. Ilicicolin H has a broad antifungal spectrum including C. albicans, Cryptococcus and A. fumigatus. Ilicicolin H can be used for the researches of cancer and infection, such as hepatocellular carcinoma (HCC) and C. albicans infection .
    Ilicicolin H
  • HY-W552257
    Hydroxypyruvic acid phosphate

    		Drug Intermediate Others
    Hydroxypyruvic acid phosphate serves as a crucial metabolic intermediate in the biosynthesis of L-Serine (HY-N0650), being formed from the conversion of the glycolytic intermediate 3-phosphoglycerate through the action of 3-phosphoglycerate dehydrogenase.
    Hydroxypyruvic acid phosphate
  • HY-126278
    Z1609609733

    		Phosphoglycerate Dehydrogenase (PHGDH) Cancer
    Z1609609733 (Compound 18) is a non-covalent 3-Phosphoglycerate dehydrogenase (PHGDH) inhibitor with an IC50 of 1.46 μM. Z1609609733 significantly inhibits serine synthesis and cancer metabolism with complete abrogation of cell proliferation .
    Z1609609733
  • HY-160252
    PHGDH-IN-4

    		Phosphoglycerate Dehydrogenase (PHGDH) Cancer
    PHGDH-IN-4 is a phosphoglycerate dehydrogenase (PHGDH) inhibitor. PHGDH-IN-4 can be used for the research of cancer .
    PHGDH-IN-4
  • HY-178989
    PGK1-IN-2

    		Phosphoglycerate Kinase (PGK) Cuproptosis Cancer
    PGK1-IN-2 (Compound 60) is a PGK1 inhibitor with an IC50 of 8.24 μM. PGK1-IN-2 demonstrates a significant ability to inhibit the proliferation of osteosarcoma cells. PGK1-IN-2 interferes with the glycolytic pathway of tumor cells by inhibiting PGK1. PGK1-IN-2 inhibits cell migration and invasion, and induces cell S phase and G2-M phase cycle arrest. PGK1-IN-2 may kill cells by inducing cuproptosis. PGK1-IN-2 shows a significant anti-tumor effect in the MNNG-HOS osteosarcoma xenograft mouse model. PGK1-IN-2 can be used for the study of osteosarcoma .
    PGK1-IN-2
  • HY-177944
    DC-PGKI

    		Phosphoglycerate Kinase (PGK) Keap1-Nrf2 Interleukin Related Inflammation/Immunology
    DC-PGKI is an orally active ATP-competitive PGK1 inhibitor(IC50 = 0.16 Μm, Kd = 99.08 nM). DC-PGKI stabilizes PGK1 in vitro and in vivo, and suppresses both glycolytic activity and the kinase function of PGK1. DC-PGKI-mediated inhibition of PGK1 leads to the accumulation of NRF2 (nuclear factor-erythroid factor 2-related factor 2, NFE2L2), which then translocates to the nucleus, binds to the proximal regions of IL-1β and IL-6 genes, and suppresses the LPS-induced expression of these genes. DC-PGKI can be used for the study of colitis .
    DC-PGKI
  • HY-138877A
    Phosphoglycolic acid lithium

    		Phosphatase Cancer
    Phosphoglycolic acid (lithium) is a competitive inhibitor of phosphoglycerate mutase (PGAM)-B, an enzyme of the glycolytic pathway. Phosphoglycolic acid increases basal and fMLF-induced levels of G6P in intact neutrophils. Phosphoglycolic acid thereby increases upstream intermediates in neutrophils, thereby amplifying the respiratory oxidative burst .
    Phosphoglycolic acid lithium
  • HY-15154R
    NG 52 (Standard)

    Compound 52 (Standard)

    		 CDK Reference Standards Cancer
    NG 52 (Standard) is the analytical standard of NG 52. This product is intended for research and analytical applications. NG 52 is a potent, cell-permeable, selective, ATP-compatible and orally active Cdc28p and Pho85p kinase inhibitor with IC50s of 7 μM and 2 μM, respectively. NG 52 also inhibits the activity of phosphoglycerate kinase 1 (PGK1) with an IC50 of 2.5 μM. NG 52 is inactive against yeast kinases Kin28p, Srb10, and Cak1p .
    NG 52 (Standard)
  • HY-182811
    AT-051/43421517

    		MAP4K Apoptosis Neurological Disease
    AT-051/43421517 is a cytoprotective agent and apoptosis inhibitor that binds to human phosphoglycerate kinase 1 (hPgk1). AT-051/43421517 protects cells from rotenone-induced cell death without inducing cell proliferation. AT-051/43421517 can be used for the research of parkinson’s disease .
    AT-051/43421517
  • HY-W552257A
    Hydroxypyruvic acid phosphate lithium

    		Drug Intermediate Others
    Hydroxypyruvic acid phosphate lithium serves as a crucial metabolic intermediate in the biosynthesis of L-Serine (HY-N0650), being formed from the conversion of the glycolytic intermediate 3-phosphoglycerate through the action of 3-phosphoglycerate dehydrogenase.
    Hydroxypyruvic acid phosphate lithium
  • HY-180597
    3-Phospho-D-glycerate

    		Nucleoside Antimetabolite/Analog Metabolic Disease
    3-Phospho-D-glycerate can be converted to 2-phospho-d-glycerate (2-PGA) via phosphoglycerate mutase .
    3-Phospho-D-glycerate
  • HY-E70976
    3-Phosphoglyceric Phosphokinase, Baker's yeast (S. cerevisiae)

    		Endogenous Metabolite Metabolic Disease
    3-Phosphoglyceric Phosphokinase, Baker's yeast (S. cerevisiae) (EC 2.7.2.3) is an enzyme that catalyzes the reversible transfer of a phosphate group from 1,3-bisphosphoglyceRate (1,3-BPG) to ADP producing 3-phosphoglyceRate (3-PG) and ATP. 3-Phosphoglyceric Phosphokinase, Baker's yeast (S. cerevisiae) (EC 2.7.2.3) is a transferase. 3-Phosphoglyceric Phosphokinase is a major enzyme used in glycolysis, in the first ATP-geneRating step of the glycolytic pathway. In gluconeogenesis, the reaction catalyzed by 3-Phosphoglyceric Phosphokinase proceeds in the opposite direction, geneRating ADP and 1,3-BPG.
    3-Phosphoglyceric Phosphokinase, Baker's yeast (S. cerevisiae)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: